Progress of daratumumab in treatment of multiple myeloma
10.3760/cma.j.cn115355-20190716-00309
- VernacularTitle:达雷木单抗治疗多发性骨髓瘤的研究进展
- Author:
Jia HU
1
;
Xiulian ZHANG
Author Information
1. 山西医科大学第一医院血液科，太原 030001
- From:
Cancer Research and Clinic
2020;32(11):807-809
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the treatment of multiple myeloma (MM) has made great breakthroughs and progress, but most patients still face tumor recurrence and refractory, which is the main cause of death in MM patients. Numerous studies have found that the use of daratumumab (anti-CD38 monoclonal antibody) targeted therapy for MM can significantly improve the patient's response rate and prolong the survival time. Furthermore, the drug is effective both in patients with relapsed/refractory MM and newly diagnosed MM. This article reviews the research progress in the mechanism, efficacy and safety of daratumumab in the treatment of MM.
